Author Archives: Patricia Inacio PhD

Adrenal Gland Masses Mostly Benign, New Zealand Study Suggests

The prevalence in New Zealand of adrenal incidentalomas, which are masses in the adrenal glands incidentally discovered during an imaging test, is similar to that of international centers, a new study found. This means that current international guidelines for managing adrenal incidentalomas likely should be applied to patients in New Zealand…

New ACTH Detection Method Improves Cure Rates in Cushing’s Disease Patients, Study Shows

Researchers have identified a new, quick method for detecting ACTH-producting tumors – called Elecsys – that can improve the cure rates of Cushing’s disease patients undergoing surgery. The study, “Long-term outcomes of tissue-based ACTH-antibody assay–guided transsphenoidal resection of pituitary adenomas in Cushing disease,” was published in the…

Precise Radiation Therapy May Also Help Cushing’s Patients Control Cortisol Levels

A type of precision radiation therapy, called stereotactic radiosurgery (SRS), helped patients with Cushing’s disease (CD) control hypercortisolism. It may be a treatment alternative for those unable to undergo surgery or whose disease recurs after surgery, a retrospective analysis reported. The study, “Stereotactic Radiosurgery for Cushing’s Disease: Results of…

Penn’s Fluorescent Dye Used During Surgery Identifies Pituitary Adenomas, a Cause of Cushing’s

Researchers at the Perelman School of Medicine at the University of Pennsylvania have successfully used a fluorescent dye to identify pituitary adenoma tissue during brain surgery. The study, “Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging,” was…

Researchers Recruiting Cushing’s Disease Patients for Osilodrostat Phase 3 Trial

A new Phase 3 clinical trial (NCT02697734) is actively recruiting Cushing’s disease patients in several countries to test the safety and effectiveness of the investigational therapy osilodrostat (LCI699). The 48-week, multicenter, randomized, double-blind, placebo-controlled study is sponsored by Novartis Pharmaceuticals. Estimated enrollment is 69 patients at 26 locations…